Cargando…

1242. Efficacy and Safety of Intravenous Fosfomycin for the Treatment of Multi-resistant Gram Negative Infections

BACKGROUND: To describe the clinical use, efficacy and safety of intravenous (IV) fosfomycin in the treatment of infections caused by Gram-negative bacteria (GNB). METHODS: Hospitalized patients who received ≥48 hours of IV fosfomycin therapy during September 27, 2017 thru January 31, 2020 were incl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdallah, Tasneem, Elajez, Reem, Ibrahim, Tawheeda, Alimam, Abeir, Omrani, Ali S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644471/ http://dx.doi.org/10.1093/ofid/ofab466.1434

Ejemplares similares

1242. Safety and Immunogenicity of Novel 24-Valent Pneumococcal Vaccine in Healthy Adults
por: Chichili, Gurunadh, et al.
Publicado: (2020)

508. Title Favipiravir for the Treatment of Coronavirus Disease 2019; A Propensity Score Matched Cohort Study
por: Alattar, Rand A, et al.
Publicado: (2021)

Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens
por: Ruiz Ramos, Jesús, et al.
Publicado: (2019)

Safety evaluation of intravenous immunoglobulin in pediatric patients: a retrospective, 1-year observational study
por: Elajez, Reem, et al.
Publicado: (2019)

In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections
por: Gopichand, Pallam, et al.
Publicado: (2019)

Intravenous fosfomycin therapy in critically ill patients infected with colistin-resistant enterobacteriacae
por: Mukherjee, DN, et al.
Publicado: (2015)

Is fosfomycin as effective as claimed on MDR Gram-negative bacteria causing UTI? [Letter]
por: Singh, Geeta, et al.
Publicado: (2019)

P1242: A TRUELY LEUKEMIC SUBPOPULATION IDENTIFIED BY SINGLE CELL SEQUENCING IN T LARGE GRANULAR LYMPHOCYTIC LEUKEMIA
por: Zhang, Lele, et al.
Publicado: (2023)

Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment
por: Kowalska-Krochmal, Beata, et al.
Publicado: (2022)

MD 1242: Injection and emittance preservation
por: Bartosik, Hannes, et al.
Publicado: (2017)

In vitro Activity of Fosfomycin against Multidrug-Resistant Urinary and Nonurinary Gram-Negative Isolates
por: Behera, Bijayini, et al.
Publicado: (2018)

Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene
por: Ito, Ryota, et al.
Publicado: (2017)

“Is Fosfomycin As Effective As Claimed On MDR Gram-Negative Bacteria Causing UTI?” [Response To Letter]
por: Gopichand, Pallam, et al.
Publicado: (2019)

976. Population Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analysis of Intravenous Fosfomycin for Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
por: Alattar, Rand A., et al.
Publicado: (2022)

In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
por: Wiederhold, Nathan P, et al.
Publicado: (2017)

Efficacy of an intravenous colistin regimen in ventilator-associated pneumonia and bacteraemia due to multiresistant Gram-negative bacteria: preliminary results
por: Frantzeskaki, F, et al.
Publicado: (2006)

Integrons as surrogate marker for multi drug resistance in gram negative bacilli
por: Kaushik, Gopalakrishnan, et al.
Publicado: (2012)

Oral and intravenous fosfomycin in complicated urinary tract infections
por: López-Montesinos, Inmaculada, et al.
Publicado: (2019)

Efficacy and safety of colistin in the treatment of infections in the ICU caused by multidrug-resistant Gram-negative organisms
por: Pavleas, J, et al.
Publicado: (2006)

1690. Oral Fosfomycin for the Treatment of Bacterial Prostatitis
por: Kamath, Meghan, et al.
Publicado: (2020)

P1242: ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
por: Zhang, Y., et al.
Publicado: (2022)

1242. Quantitative Analysis of Microbial Burden on LTCF Environmental Surfaces
por: DiBiase, Lauren, et al.
Publicado: (2018)

Decrease in intravenous antibiotic use with adjunctive aerosolized amikacin treatment in intubated mechanically ventilated patients with Gram-negative pneumonia
por: Niederman, M, et al.
Publicado: (2007)

In Vitro Activity of Newer and Conventional Antimicrobial Agents, Including Fosfomycin and Colistin, against Selected Gram-Negative Bacilli in Kuwait
por: Alfouzan, Wadha, et al.
Publicado: (2018)

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections
por: Zhanel, George G., et al.
Publicado: (2020)

Prescription Pattern of Intravenous Fosfomycin in a Provincial Hospital in Thailand
por: Thampithak, Anusorn, et al.
Publicado: (2022)

Clinical Use of Intravenous Fosfomycin in Critical Care Patients in Taiwan
por: Chen, Tzu-Ting, et al.
Publicado: (2023)

198. Evaluation of Oral Step-down versus Continued Intravenous Antimicrobial Therapy in Immunocompromised Patients Hospitalized with Gram-Negative Bacteremia
por: Savage, Heather, et al.
Publicado: (2021)

Polychlorinated Biphenyls (Aroclor 1242): Effects of Uptake on E. coli Growth
por: Keil, Julian E., et al.
Publicado: (1972)

Climatic and environmental aspects of the Mongol withdrawal from Hungary in 1242 CE
por: Büntgen, Ulf, et al.
Publicado: (2016)

1222. Fosfomycin Susceptibility Testing using the new ETEST(®)FO
por: Halimi, Diane, et al.
Publicado: (2020)

Evaluation of the combination treatments with intravenous fosfomycin for carbapenem-resistant Klebsiella pneumoniae
por: Önal, Uğur, et al.
Publicado: (2023)

Response of Caenorhabditis elegans during subsequent infections with Gram positive and Gram negative bacteria
por: Mercy, Gnanasekaran Jeba, et al.
Publicado: (2012)

The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study
por: Fajfr, Miroslav, et al.
Publicado: (2017)

Correction: Epigenetic resetting of human pluripotency (doi:10.1242/dev.146811)
por: Guo, Ge, et al.
Publicado: (2018)

1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates
por: Lijfrock, Virgil, et al.
Publicado: (2020)

Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada
por: Zhanel, George G., et al.
Publicado: (2018)

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
por: Marino, Andrea, et al.
Publicado: (2022)

Inhaled ceftazidime and amikacin versus inhaled colistin in the treatment of gram negative ventilator associated pneumonia
por: Nassar, YS, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iuavbp71rlfl5u5grlechvc3n9